AnalystBook Research · Company Intelligence

Amrize Ltd

AMRZNYSE

Built from Amrize Ltd's own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Amrize revenue was nearly flat at $11.8B, net income fell 7.0%, and free cash flow fell 13.4%.

The read at a glance✓ Audited against SEC data
  • Business mixNorth American building solutionsNote
  • RevenueRevenue rose 0.9% to $11.8BNote
  • ProfitabilityNet income fell 7.0%Watch
  • CashFree cash flow fell 13.4%Watch
  • Balance sheetEquity rose 33.7%OK
  • Insiders30 buys / 0 sells; cluster buyOK
  • AccountingAltman-Z grey; EQ safeNote

Business

Amrize is a North American building-solutions company selling cement, aggregates, ready-mix concrete, asphalt, roofing systems, and other building products from foundation to rooftop.

Where the revenue comes from

Fiscal 2025, as Amrize Ltd reports it. History and quarterly detail are in the app.

  • Building Materials$8.5B
  • Building Envelope$3.3B

Leadership changes

From Amrize Ltd's own filings, the day they're filed.

  • Ian Johnston · Chief Financial Officer · departureeff. 2026-04-01
  • Theresa Drew · Directors · departureeff. 2026-02-11
  • Holli Ladhani · appointment

Latest filings

  • 8-K · Company announcement2026-09-01
  • 8-K · Company announcement2026-08-24
  • 10-Q · Quarterly report2026-08-10
  • 8-K · Company announcement2026-08-06
  • 10-Q · Quarterly report2026-05-07
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • Main tension🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Amrize Ltd, every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.